Amivantamab added to standard drugs for untreated advanced head and neck cancer
Tests amivantamab plus standard drugs in adults with untreated advanced head and neck cancer.
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou, Jinan, Kunming, Linyi, Nanjing, Nanning, Shanghai, Wuhan, Xi'an, and Yibin, ChinaSee the 25 sitesAlso in 21 other countries, 181 sites
- Trial code
- Registry title
- A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 600 people, planned
- Started
- 3 Dec 2025
- Expected to end
- 18 Jul 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Amivantamab
- Pembrolizumab
- Carboplatin
- 5-Flurouracil
- Cisplatin
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with head and neck squamous cell cancer that has come back or spread and cannot be cured by local treatment. They must not have had any drug treatment yet for this stage.
- Age
- 18 years or older (or the legal age of adulthood where the study takes place, if higher).
- Sex
- All sexes can join.
- Disease stage
- Squamous cell cancer of the head and neck that has come back or spread, confirmed under the microscope, that local treatment cannot remove. The cancer must start in the mouth, oropharynx, hypopharynx or larynx. It must be measurable by scan (RECIST v.1.1). Activity level (ECOG) must be 0 or 1.
- Earlier treatment
- No earlier drug (systemic) treatment for the recurrent or metastatic cancer.
- Biomarker or test result
- For tumors starting in the oropharynx, HPV status must be known. Any known p16, HPV DNA or high-risk HPV test result must be negative.
Main reasons for not taking part
- Cancer starting in the nasopharynx, or a primary tumor of unknown location
- Uncontrolled illness
- Untreated brain metastases or known leptomeningeal disease
- Clinically significant heart or blood vessel disease
- Not enough organ or bone marrow function
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Be more than or equal to (>=) 18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place, whichever is greater)
- Have histologically or cytologically confirmed recurrent/metastatic (R/M) HNSCC that is considered incurable by local therapies: a. eligible primary tumor locations are the oral cavity, oropharynx, hypopharynx, or larynx; b. Must not have a primary tumor site of nasopharynx or primary tumor of unknown location; c. Must have documented local testing results per local regulations; d. Human papillomavirus (HPV) status must be known for participants with primary tumor location in oropharynx via p16 test, HPV DNA test, or high-risk HPV in situ hybridization (ISH). Any known p16, HPV DNA, or high-risk HPV ISH status of tumor must be negative
- Be treatment-naive for systemic therapy in the R/M setting
- Have an ECOG performance status of 0 or 1
- Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1
Who cannot take part
- Have an uncontrolled illness
- Have untreated brain metastases or history of known presence of leptomeningeal disease
- Have a history of clinically significant cardiovascular disease
- Known allergies, hypersensitivity, contraindications, or intolerance to excipients of: Amivantamab, Pembrolizumab, Carboplatin, Cisplatin, 5-FU and Hyaluronidase
- Inadequate organ or bone marrow function
This trial is currently available in China.
Also in 21 other countries, 181 sites
- Beijing Cancer HospitalBeijing, ChinaTaking people
- Cancer Hospital, Chinese Academy of Medical SciencesBeijing, ChinaTaking people
- Tongren Hospital Outpatient BldgBeijing, ChinaTaking people
- The Affiliated Hospital of Bengbu Medical CollegeBengbu, ChinaTaking people
- Hunan Cancer HospitalChangsha, ChinaTaking people
- The Second Xiangya Hospital of Central South UniversityChangsha, ChinaTaking people
- Sichuan Cancer HospitalChengdu, ChinaTaking people
- Sichuan Provincial Peoples HospitalChengdu, ChinaTaking people
- West China Hospital,Sichuan UniversityChengdu, ChinaTaking people
- Chongqing Cancer HospitalChongqing, ChinaTaking people
- Dongguan People's HospitalDongguan, ChinaTaking people
- Sun Yat-sen University Cancer HospitalGuangzhou, ChinaTaking people
- Zhejiang Cancer HospitalHangzhou, ChinaTaking people
- The Affiliated Cancer Hospital of Shandong First Medical UniversityJinan, ChinaTaking people
- Yunnan Cancer HospitalKunming, ChinaTaking people
- LinYi Cancer HospitalLinyi, ChinaTaking people
- Nanjing Drum Tower hospitalNanjing, ChinaTaking people
- The Cancer Hospital Affiliated to Guangxi Medical UniversityNanning, ChinaTaking people
- Fudan Cancer HospitalShanghai, ChinaTaking people
- Shanghai East HospitalShanghai, ChinaTaking people
- Tongji Hospital Tongji Medical College of HustWuhan, ChinaTaking people
- Union Hospital Tongji Medical College of Huazhong University of Science and TechnologyWuhan, ChinaTaking people
- Wuhan University Zhongnan HospitalWuhan, ChinaTaking people
- The First Affiliated Hospital of Xian Jiaotong UniversityXi'an, ChinaTaking people
- Yibin Second People's HospitalYibin, ChinaTaking people
About the trial
What the trial wants to find out
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
The 2 groups in the trial
- Arm A: Pembrolizumab, Amivantamab, CarboplatinTreatment being tested
Participants will receive pembrolizumab, amivantamab and carboplatin.
Treatment: Amivantamab, Pembrolizumab, and Carboplatin
- Arm B: Pembrolizumab, 5-Flurouracil (5-FU), Carboplatin or CisplatinExisting treatment, for comparison
Participants will receive pembrolizumab, 5-FU and carboplatin or cisplatin (platinum therapy).
Treatment: Pembrolizumab, Carboplatin, 5-Flurouracil, and Cisplatin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Plain-language title
- Amivantamab added to standard drugs for untreated advanced head and neck cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 November 2026